VIDEO: Terns Pharma ‘builds upon pipeline’ of NASH, obesity research

In a Healio video exclusive, Diana Chung, chief development officer at Terns Pharmaceuticals, highlights data on TERN-501, a thyroid hormone receptor beta-agonist for patients with nonalcoholic steatohepatitis.At the 2022 International Liver Congress, Terns conducted five oral and poster presentations on data from three programs, including TERN-501, which recently was evaluated in the company’s first-in-human study. Results showed TERN-501 was safe and well-tolerated in patients across all doses, Chung reported.“We were very excited to be able to present this data at EASL, and itRead More

Categories: News

Related Articles

Resmetirom ‘has potential to be first medication approved’ for patients with NASH

LONDON — Resmetirom was safe and well tolerated at 100 mg and 80 mg doses in patients with nonalcoholic steatohepatitis, according to late-breaking research presented…

HIV an independent risk factor for nonalcoholic steatohepatitis

A study of more than 1,300 women demonstrated that HIV is an independent risk factor for nonalcoholic steatohepatitis with significant nonalcoholic fatty liver disease activity…

Researchers assemble first complete human genome sequence

A team of researchers assembled the first complete sequence of a human genome, 2 decades after the Human Genome Project formed the first incomplete draft…

Growth hormone reduces liver fat, inflammation in adults with NAFLD

ATLANTA — Adults with overweight or obesity and nonalcoholic fatty liver disease, or NAFLD, had a significant reduction in liver fat and inflammation with daily…

Sex hormone-binding globulin level may predict liver fibrosis for men with NAFLD

SAN DIEGO — Higher sex hormone-binding globulin levels may predict liver fibrosis for men with nonalcoholic fatty liver disease, according to a presenter at the…